Germame Ajebo, Paul Dainer, Jeremy Pantin, Nathan Ryan and Charles Bruker
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by immune-mediated destruction of otherwise normal platelets and can be either primary, without obvious initiating or underlying cause, or secondary ITP due to an underlying disease or drug exposure.
The goals of therapy for ITP include achieving an adequate platelet level for hemostasis and minimizing toxicities with current options including: corticosteroids, rituximab, splenectomy, intravenous gamma globulin (IVIG), Anti-D, and thrombopoietin receptor agonists (TPO) like romiplostim and eltrombopag.
TPO mimetics like romiplostim have emerged as viable and practical option in relapsed and refractory ITP. We present a 70-year-old Caucasian male patient with chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) related secondary ITP who had been maintained for nearly a decade on romiplostim after failing all other options of therapy. We report this case to demonstrate the efficacy and sustainability of romiplostim use in the relapse/ refractory ITP in such a patient who failed to respond to other therapeutic options.
PDFShare this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report
